RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE)
A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Sponsor: EpicentRx, Inc.
Terminated
Low Enrollment
Other terminated trials from EpicentRx, Inc.
- Carcinoma, Small Cell Lung · Phase PHASE3 · Mar 2024
- Advanced Cancer · Phase PHASE1 · Dec 2019
- Cholangiocarcinoma · Phase PHASE2 · May 2016
- Lymphomas · Phase PHASE1 · Jan 2016
More terminations from EpicentRx, Inc.
This PHASE1 trial investigates Brain Tumor, Pediatric and Brain Tumor, Recurrent and is currently terminated or withdrawn. EpicentRx, Inc. leads this study, which shows 15 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Nov 2024 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Terminated PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Oct 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
May 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Apr 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EpicentRx, Inc.
- Texas Children's Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .